Physician profile
Ahmed Morales Jorge
NPI 1265546592
$213,936.31
in general payments reported to CMS, 2019-2025
18 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,297 · 2021: $37K · 2022: $35K · 2023: $36K · 2024: $53K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Consulting Fee: $14K · Travel and Lodging: $13K · Food and Beverage: $6,797 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,745.20 |
| Consulting Fee | $13,950.00 |
| Travel and Lodging | $12,842.45 |
| Food and Beverage | $6,797.12 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $91,368.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $48,528.76 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $24,033.63 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $17,901.46 | 2020-2025 | Tremfya, Stelara |
| Pfizer INC. | $16,541.51 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $7,826.94 | 2019-2025 | Tremfya, Stelara, Xarelto |
| Merck Sharp & Dohme LLC | $4,770.63 | 2019-2021 | |
| Celgene Corporation | $1,200.00 | 2023-2024 | Zeposia |
| Pbg Puerto Rico LLC | $471.78 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $437.70 | 2023-2025 | Entyvio |
| Pfizer Pharmaceuticals LLC | $181.00 | 2019 | |
| Organon LLC | $177.03 | 2022-2023 | Renflexis |
| Gilead Sciences, INC. | $161.47 | 2022-2024 | |
| Johnson and Johnson International | $148.99 | 2022 | |
| Madrigal Pharmaceuticals | $100.68 | 2024 | Rezdiffra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43.20 | 2021-2023 | Amjevita |
| Genzyme Corporation | $21.75 | 2023 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $21.40 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Morales Jorge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.